Aptose Biosciences, Inc. (APTO) financial statements (2022 and earlier)

Company profile

Business Address 251 CONSUMERS ROAD
TORONTO, ON M2J 4R3
State of Incorp. ON
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments79,128122,39397,60015,739
Cash and cash equivalents39,114117,39379,84215,299
Short-term investments40,0145,00017,758440
Prepaid expense2,4762,5541,025646
Other current assets133129141101
Total current assets:81,737125,07698,76616,486
Noncurrent Assets
Operating lease, right-of-use asset4659251,376
Property, plant and equipment323261334384
Total noncurrent assets:7881,1861,710384
TOTAL ASSETS:82,525126,262100,47616,870
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,7156,2735,0182,789
Accounts payable1,6992,1711,9601,315
Accrued liabilities6,0164,1023,0581,474
Debt  521 
Other undisclosed current liabilities459539  
Total current liabilities:8,1746,8125,5392,789
Noncurrent Liabilities
Long-term debt and lease obligation1155351,011 
Operating lease, liability1155351,011
Other undisclosed noncurrent liabilities(115)(535)  
Total noncurrent liabilities:1155351,011 
Total liabilities:8,2897,3476,5502,789
Stockholders' equity
Stockholders' equity attributable to parent74,236118,91593,92614,081
Common stock437,386429,523365,490261,072
Additional paid in capital63,67350,86134,64932,963
Accumulated other comprehensive loss(4,316)(4,316)(4,298)(4,316)
Accumulated deficit(422,507)(357,153)(301,915)(275,638)
Total stockholders' equity:74,236118,91593,92614,081
TOTAL LIABILITIES AND EQUITY:82,525126,262100,47616,870

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(65,447)(55,768)(26,857)(29,107)
Operating loss:(65,447)(55,768)(26,857)(29,107)
Nonoperating income93530580239
Investment income, nonoperating94522574283
Net loss available to common stockholders, diluted:(65,354)(55,238)(26,277)(28,868)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(65,354)(55,238)(26,277)(28,868)
Other comprehensive income (loss) (18)18 
Comprehensive loss, net of tax, attributable to parent:(65,354)(55,256)(26,259)(28,868)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: